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Introduction
Heart failure is the leading cause of  death in the Western world (1). Defective calcium (Ca2+) cycling, such 
as decreased Ca2+ uptake in the sarcoplasmic reticulum (SR) or SR calcium leak occurs in failing hearts 
(2, 3), and genetic mutations in calcium-handling genes cause arrhythmias and dilated cardiomyopathy 
(DCM) (4). Altered expression of  calcium-handling genes perturbs contractility (5–9), but relatively little is 
known about how the expression of  these genes is coordinated in the heart.
Mediator is a multiprotein complex of  about 30 subunits that form the core and kinase submodules (10, 
11). The kinase submodule, containing MED12, MED13, CDK8, and Cyclin C (12), can repress transcrip-
tion through allosteric inhibition of  RNA Pol II binding to the core submodule (13) but can also activate 
transcription by promoting Pol II recruitment to target genes via specific transcription factors (14). We previ-
ously demonstrated that cardiac MED13 regulates systemic energy homeostasis through signaling to extra-
cardiac tissues (15, 16), but the roles of  the other kinase components in the heart have not been investigated.
MED12, a component of  the Mediator kinase submodule, is encoded on the X chromosome, and 
missense mutations are associated with a variety of  X-linked disorders (17–19). Developmental signaling 
pathways and transcription factors converge on MED12, which acts as a transcriptional hub required to 
coordinate development (20–23). Deletion of  Med12 in Drosophila decreases expression of  sonic hedge-
hog target genes and leads to defects in eye development (20), and mutations in Med12 in zebrafish 
disrupt SOX-mediated transcription during endoderm development (22). MED12 is also required for 
neuron development through its regulation of  TBX2B in zebrafish (23). Med12 hypomorphic mutant 
mice die in utero due to various developmental defects (24, 25), but the function of  MED12 in the heart 
has not yet been investigated.
The Mediator complex regulates gene transcription by linking basal transcriptional machinery 
with DNA-bound transcription factors. The activity of the Mediator complex is mainly controlled 
by a kinase submodule that is composed of 4 proteins, including MED12. Although ubiquitously 
expressed, Mediator subunits can differentially regulate gene expression in a tissue-specific 
manner. Here, we report that MED12 is required for normal cardiac function, such that mice with 
conditional cardiac-specific deletion of MED12 display progressive dilated cardiomyopathy. Loss of 
MED12 perturbs expression of calcium-handling genes in the heart, consequently altering calcium 
cycling in cardiomyocytes and disrupting cardiac electrical activity. We identified transcription 
factors that regulate expression of calcium-handling genes that are downregulated in the heart 
in the absence of MED12, and we found that MED12 localizes to transcription factor consensus 
sequences within calcium-handling genes. We showed that MED12 interacts with one such 
transcription factor, MEF2, in cardiomyocytes and that MED12 and MEF2 co-occupy promoters of 
calcium-handling genes. Furthermore, we demonstrated that MED12 enhances MEF2 transcriptional 
activity and that overexpression of both increases expression of calcium-handling genes in 
cardiomyocytes. Our data support a role for MED12 as a coordinator of transcription through MEF2 
and other transcription factors. We conclude that MED12 is a regulator of a network of calcium-
handling genes, consequently mediating contractility in the mammalian heart.
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In this study, we investigated the function of  MED12 in the heart by deleting Med12 in cardio-
myocytes (CMs). Mice with cardiac-specific deletion of  Med12) suffer from early-onset DCM. Loss 
of  Med12 alters expression of  calcium-handling genes, ultimately disrupting calcium cycling in CMs 
and resulting in decreased cardiac function. MED12 regulates expression of  calcium-handling genes 
in part by coordinating transcription through MEF2 and several other transcription factors, but loss 
of  MED12 does not affect MEF2-DNA binding or RNA Pol II recruitment. Our findings demonstrate 
that MED12 controls the transcriptional network of  calcium-handling genes, consequently mediating 
contractility in the heart.
Results
Cardiac-specific deletion of  Med12 causes DCM. Med12 is highly expressed in the heart during early embryonic 
development but declines after E15.5 and is expressed at similar levels in the neonatal and adult mouse 
heart (Figure 1A). To investigate the function of  MED12 in the heart, we crossed Med12fl/fl female mice 
(24) with male mice expressing the αMhc-Cre transgene, which is expressed in a CM-specific manner (26). 
αMhc-Cre+ male mice with a single-floxed Med12 allele (αMhc-Cre+Med12fl/y, abbreviated as Med12cKO) had 
significantly less cardiac Med12 expression than αMhc-Cre–Med12fl/y (CTL) mice in whole heart (Figure 1B). 
Because αMhc-Cre expression is CM specific, Med12 mRNA was not detected in CMs isolated from Med-
12cKO hearts (Figure 1B), confirming efficient deletion of  Med12.
Male and female Med12cKO mice were born at the expected Mendelian ratios and appeared identi-
cal to littermate controls. Hearts of  Med12cKO mice were indistinguishable morphologically from CTL 
hearts at birth but displayed ventricular wall thinning and dilation by postnatal day 7 (P7) (Figure 1C). 
By 5 weeks of  age, Med12cKO hearts weighed significantly more than CTL hearts, which was exacerbat-
ed at 12 weeks of  age (Figure 1D). Echocardiography performed on unanesthetized male mice revealed 
parameters indicative of  cardiac dysfunction. Fractional shortening, a measure of  cardiac contractility, was 
significantly reduced in Med12cKO mice as early as P7 and declined progressively with age (Figure 1E and 
Supplemental Figure 1; supplemental material available online with this article; https://doi.org/10.1172/
jci.insight.91920DS1). Heart rate was significantly decreased in Med12cKO mice by P7 and remained low-
er throughout adulthood (Figure 1F). Left ventricular posterior wall thickness in diastole (LVPWD) and 
systole (LVPWS) were decreased by P7 and continued to decline, indicating early and progressive thinning 
of  the left ventricular wall (Figure 1, G and H). Left ventricular internal dimension in diastole (LVIDD) 
and systole (LVIDS) were already increased at P7 and continued to increase with aging, indicating signif-
icant dilation of  the left ventricular chamber (Figure 1, I and J). Female mice with mosaic Med12 expres-
sion in the heart (αMhc-Cre+Med12fl/+) had slightly decreased cardiac function, and complete loss of  Med12 
(αMhc-Cre+Med12fl/fl) in females significantly decreased cardiac function to nearly the same degree as in 
male Med12cKO mice (Supplemental Figure 1, B and C, and Supplemental Table 1).
DCM is characterized by ventricular chamber enlargement and cardiac dysfunction with no heart 
wall hypertrophy. In some cases, prominent fibrosis accompanies late-stage DCM (27). Masson’s tri-
chrome staining of  adult male Med12cKO hearts demonstrated an increase in interstitial cardiac fibrosis 
(Figure 2A). Quantification of  cardiac fibrosis using Picrosirius red staining revealed a slight increase in 
fibrosis at P7, which was significant at 12 weeks of  age (Figure 2, B and C). Despite increased fibrosis in 
Med12cKO hearts, no differences in CM death were detected (Supplemental Figure 2, A–C). Additionally, 
differences in CM proliferation were unchanged in hearts from Med12cKO mice (Supplemental Figure 2, 
D–F). We also analyzed CM ultrastructure by electron microscopy and observed that sarcomeric struc-
ture in Med12cKO hearts was identical to control hearts throughout most regions of  the heart (Figure 
2D, middle panel), with only a few regions containing disorganized sarcomeres (Figure 2D, right panel).
To determine whether cardiac conduction is altered in Med12cKO mice, as often occurs in patients with 
DCM (28), electrocardiography was performed on anesthetized Med12cKO mice. Adult male Med12cKO 
mice had decreased heart rates when anesthetized (Figure 2E), to the same degree as observed in the 
unanesthetized state (Figure 1F). Loss of  Med12 in the heart leads to abnormal cardiac electrical activity, 
specifically a prolongation of  the QRS interval (Figure 2, F and G). These results indicate that Med12 is 
required to maintain normal cardiac function and that loss of  cardiac Med12 causes early-onset DCM.
Deletion of  Med12 alters expression of  calcium-handling genes in the heart. To gain an understanding of  how 
loss of  Med12 leads to DCM, we performed RNA-Seq on ventricles from mice at P1, before Med12cKO 
mice develop DCM. We identified 103 genes that were significantly upregulated and 97 genes that were 
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significantly downregulated in Med12cKO ventricles by at least 1.5-fold with P < 0.05 (Figure 3A). The Medi-
ator kinase submodule can be composed of  MED12, MED13, and CDK8 (12) or their respective paralogs 
MED12-like (MED12L), MED13-like (MED13L), and CDK8-like (CDK19), in a mutually exclusive man-
ner (11). Although Med12 and Med12l have similar developmental expression patterns in the mouse heart 
(Figure 1A and Supplemental Figure 3A), deletion of  Med12 did not lead to a compensatory upregulation 
of  Med12l (Supplemental Figure 3B). Furthermore, expression of  other Mediator subunits in the heart was 
unaffected by deletion of  Med12 (Supplemental Figure 3B).
Gene Ontology (GO) analysis identified the top processes regulated in Med12cKO hearts as the mus-
cle system, suggesting the importance of  Med12 in regulating contractility of  the heart (GSE100089; 
https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE100089) (Figure 3B). Using Ingenuity 
Pathway Analysis, we discovered that the top pathway altered in Med12cKO hearts was calcium sig-
naling (Figure 3C). Based on this finding, we identified calcium-handling genes that were significantly 
downregulated (Atp2a2, Gja1 and -5, Kcnn1, Pln, Ryr2, and Tnnt1), and upregulated (Cacna1d, Casq1, 
Gja3, and Slc8a2) in Med12cKO hearts by RNA-Seq (Figure 3D). We quantified the expression of  many 
Figure 1. Deletion of Med12 in cardiomyocytes impairs cardiac function. (A) Med12 mRNA expression in ventricles during development and aging of 
mouse hearts. n = 3. (B) Med12 expression in hearts (n = 5) and cardiomyocytes (CMs) from control (CTL) and Med12cKO (cKO) male mice (n = 4–5 mice). (C) 
H&E staining and whole-mount heart representations of CTL and cKO male hearts. Scale bars: 1 mm. Serial sections are shown in C and Figure 2, A and 
B. LV, left ventricle. (D) Heart weight (HW) to tibia length (TL) analysis. n = 5. (E) Fractional shortening, (F) heart rate, (G) left ventricular posterior wall 
thickness in diastole (LVPWD) and (H) in systole (LVPWS), (I) left ventricular internal dimension in diastole (LVIDD) and (J) in systole (LVIDS) of CTL and 
cKO male hearts. n = 5–8. Data are mean ± SEM. *P < 0.05 by 2-tailed Student’s t test.
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calcium-handling genes by qPCR in independent ventricular samples from P1, P 7, P14, and 8 week-
old Med12cKO mice and in CMs isolated from adult hearts. All calcium-related genes investigated were 
significantly regulated at P1, before the onset of  DCM, and remained significantly down- or upregu-
lated in hearts and CMs of  adult mice (Figure 3, E and F). These results suggest that gene expression 
perturbation precedes structural and functional changes in Med12cKO hearts.
To determine the functional consequences of  altered gene expression, we quantified levels of  key cal-
cium-handling proteins. In response to an action potential, Ca2+ influx into CMs triggers calcium-induced 
Figure 2. Absence of Med12 in cardiomyocytes alters electrical activity of the heart. (A) Masson’s trichrome staining and (B) Picrosirius red staining of CTL and 
cKO hearts. Scale bars: 1 mm. LV, left ventricle. (C) Quantification of Picrosirius red staining of fibrosis (n = 3) in heart sections from 3 mice per group. (D) Represen-
tative transmission electron microscopy images of CTL and cKO LVs from 8-week-old male mice. Scale bars: 2 μm. (E) Heart rate, (F) representative electrocardio-
gram tracings, and (G) quantification of QRS length in 6-week-old adult male hearts. n = 8, E and G. Data are mean ± SEM. *P < 0.05 by 2-tailed Student’s t test.
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calcium release from the SR through the ryanodine receptor (RyR), leading to CM contraction. Protein 
levels of  RyR were decreased in Med12cKO hearts at P7 and were significantly reduced in CMs isolated 
from hearts of  8-week-old Med12cKO mice (Figure 3, G and H). CM relaxation is regulated by signal-
ing pathways that restore intracellular and SR Ca2+ to resting concentrations. These pathways converge 
on SERCA2a, which rapidly pumps Ca2+ into the SR, decreasing the cytosolic intracellular Ca2+ concen-
tration. SERCA2a protein levels were decreased at P7 and 8 weeks in Med12cKO CMs and hearts. Total 
protein levels of  phospholamban (PLN), an inhibitor of  SERCA2a, were not significantly changed in P7 
or 8 week-old ventricles, but PLN was hyperphosphorylated in Med12cKO CMs and hearts (Figure 3, G 
and H). The phosphorylation of  PLN is known to potently relieve its inhibitory effects on SERCA2a, 
Figure 3. MED12 regulates calcium-handling 
genes in the heart. (A) Heat map of differen-
tially expressed genes in CTL and Med12cKO 
(cKO) ventricles at P1, analyzed by RNA-Seq with 
cutoff of P < 0.05 and 1.5 fold change. n = 3. (B) 
Gene Ontology Analysis and (C) Ingenuity Path-
way Analysis of differentially expressed genes 
in CTL and cKO ventricles. (D) Calcium-handling 
genes are differentially expressed in CTL and 
cKO ventricles (RNA-Seq data). (E) qPCR analysis 
of calcium-handling genes downregulated and 
(F) upregulated in cKO ventricles. n = 4. All genes 
in D–F are significantly regulated in Med12cKO 
ventricles. (G) Protein levels in hearts and CMs 
from CTL and cKO male mice. Ryr, ryanodine 
receptor; SERCA2a, sarcoplasmic reticulum Ca2+ 
ATPase 2a; PLN, total phopholamban; CX43, 
connexin 43. (H) Quantification of Western blots 
from 6–8 mice. Data are mean ± SEM. *P < 0.05 
by 2-tailed Student’s t test.
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resulting in increased SERCA activity and enhanced 
calcium cycling. We also observed a significant decrease 
in the gap junction protein connexin-43 (CX43) in P7 
Med12cKO hearts, and they remained decreased at 8 
weeks of  age in ventricles and in isolated CMs (Figure 
3, G and H). Taken together, altered calcium-handling 
gene and protein levels in Med12cKO hearts support the 
hypothesis that MED12 coordinately regulates calcium 
handling in the heart.
MED12 regulates calcium handling in CMs. To deter-
mine the functional consequence of  altered calci-
um-handling gene and protein expression, we mea-
sured Ca2+ flux in adult CMs. Loss of  Med12 increased 
peak Ca2+ transients without altering diastolic Ca2+ 
levels (Figure 4, A and B), indicating that more Ca2+ 
is released during each contraction-relaxation cycle 
in Med12cKO CMs. Reuptake of  Ca2+ into the SR was 
accelerated in Med12cKO CMs, as demonstrated by a 
faster cytosolic Ca2+ transient decay rate (τ) and reduced 
duration of  the Ca2+ transient (Figure 4, C and D). We 
also observed an increase in CM fractional shortening, 
suggesting enhanced contractility in Med12cKO CMs 
(Figure 4E). To determine whether changes in Ca2+ 
transients were due to altered SR calcium content, we 
measured SR Ca2+ load using caffeine. Total SR Ca2+ 
content is unchanged in Med12cKO CMs (Figure 4F), 
indicating that it is the cycling of  Ca2+ that is altered 
in adult Med12cKO CMs, rather than the total levels of  
Ca2+ available in the SR.
Perturbed Ca2+ cycling in CMs could be a cause 
or consequence of  cardiac dysfunction in adult Med-
12cKO hearts. Because cardiac function was already 
decreased in Med12cKO mice at P7 (Figure 1E), we 
measured Ca2+ flux in CMs isolated from P1 hearts. 
Similar to adult CMs, loss of  Med12 did not alter dia-
stolic Ca2+ levels but increased peak Ca2+ transients, 
Ca2+ decay rate, and duration of  Ca2+ transients in P1 
CMs (Figure 4, G–J). These data demonstrate that 
altered calcium handling precedes cardiac dysfunction 
in Med12cKO mice, indicating that it is likely the cause 
of  early-onset DCM.
Figure 4. MED12 regulates calcium handling in cardiomyo-
cytes. (A) Adult mouse cardiomyocytes (CM) isolated from 
8-week-old male CTL and cKO ventricles and representative 
calcium tracings. Scale bars: 100 µm. (B) Peak Ca2+ transients, 
(C) transient decay rate (τ), (D) time to 50% decay, (E) frac-
tional shortening, (F) and SR Ca2+ load in CMs from CTL and 
cKO adult male mice. (G) Representative calcium transients 
from neonatal CM isolated from P1 male CTL and cKO ventri-
cles. (H) Peak Ca2+ transients, (I) transient decay rate, and (J) 
time to 50% decay in CMs from CTL and cKO neonatal male 
mice. For B–F and H–J, n = 16 cardiomyocytes per heart and n = 
3–4 hearts per group. For simplicity, data points are averages 
of CM calcium measurements from each animal. Data are 
average ± SEM. *P < 0.01 by 2-tailed Student’s t test.
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MED12 facilitates cooperative transcription of  calcium-handling genes in the heart. To gain an understanding 
of  how MED12 regulates gene expression in the heart, we performed Ingenuity Pathway upstream regu-
lator analysis (URA) (29). URA is an unbiased analysis that identifies upstream transcriptional regulators 
of  gene-expression changes based on reports in the literature. The results, displayed as a z-score, infer the 
activation or inactivation state of  the transcription factor. Using URA, we identified likely upstream regu-
lators of  genes differentially expressed in Med12cKO ventricles. Loss of  Med12 was predicted to inhibit the 
activities of  transcription factors known to regulate calcium-handling gene expression, including CEBP, 
MEF2, CREB, EGR1, STAT3, and STAT1 (Figure 5A) (30). With the exception of  Egr1, which was down-
regulated, deletion of  Med12 did not affect expression of  these transcription factors in the heart (Supple-
mental Figure 4A). This analysis suggests that MED12 works with these transcription factors to regulate 
the expression of  calcium-handling genes.
Mediator subunits can cooperatively bind multiple transcription factors to regulate gene expression 
(31), and we investigated whether this was the case for MED12 in the heart. SynoR is a genome-mining soft-
ware that predicts synonymous regulation of  genes based on clusters of  transcription factor binding sites 
(TFBS). We used SynoR to identify genes containing conserved binding sites for the upstream regulators of  
calcium genes in Med12cKO hearts (CEBP, MEF2, CREB, EGR1, STAT3, and STAT1) (32). Genes with 
conserved TFBS that were significantly regulated in Med12cKO ventricles were identified and categorized 
based on the number of  TFBS. For example, conserved consensus sequences of  all 6 TFs were identified 
within Atp2a2 (Figure 5C), 5 TFBS were identified in Gja1, 4 TFBS were identified in Ryr2, and 3 TFBS 
were identified in Pln (Supplemental Figure 4, B–E). We generated a circos plot to visualize regulatory pat-
terns of  genes based on TFBS of  likely upstream TFs regulated by cardiac MED12 (Figure 5B). Of  the 200 
genes significantly regulated in Med12cKO hearts, 22 are associated with at least 4 TFBS for CEBP, MEF2, 
CREB, EGR1, STAT3, and STAT1. These genes control structural and contractile properties of  CMs, and 
they regulate cardiac development and ion channel activity. Over a third of  the genes containing TFBS reg-
ulate calcium handling in CMs (Figure 5B and Supplemental Table 2). Identification of  conserved consen-
sus sequences for CEBP, MEF2, CREB, EGR1, STAT3, and STAT1 within calcium-handling genes pro-
vides additional support that MED12 regulates calcium-handling genes through these transcription factors.
Because most calcium-handling genes are repressed in the absence of  MED12 (Figure 3), and they 
are regulated by transcription factors that are inhibited in the absence of  MED12 (Figure 5A), we tested 
whether MED12 colocalizes with TFBS on calcium-handling genes. We performed ChIP on nuclear 
fractions of  CMs isolated from CTL and Med12cKO ventricles. We probed for the interaction between 
MED12 and regions of  calcium-handling genes identified by SynoR that contain multiple TFBS, such as 
within Atp2a2 (Figure 5C). PCR was performed on ChIP samples using primers flanking TFBS in Atp2a2, 
Gja1, Ryr, Pln, and Cacna1d (Supplemental Figure 4, D–G). We found that MED12 interacts with several 
regions on Atp2a2, Gja1, and Ryr, but not with Pln or Cacna1d or in regions devoid of  predicted TFBS 
(negative controls [nc]) (Figure 5D). Additionally, the genomic regions that associate with MED12 on 
Atp2a2, Gja1, and Ryr contain predicted TFBS for CEBP, MEF2, CREB, EGR1, STAT3, and STAT1 
(Supplemental Figure 4, D–G).
MED12 interacts with MEF2. To determine whether MED12 interacts with the predicted URA transcription 
factors, we performed coimmunoprecipitation. Conserved MEF2 consensus binding sites are located within 
the amplified regions of Atp2a2, Gja1, and Ryr2 identified by MED12 ChIP (Figure 5D). Therefore, we investi-
gated whether MED12 interacts with MEF2 in CMs. MED12 was immunoprecipitated from nuclear fractions 
of CMs isolated from CTL and Med12cKO hearts, and the precipitate was probed for MED12 and MEF2. We 
discovered that MED12 interacts with MEF2 in CTL but not in Med12cKO CMs, suggesting that MED12 can 
regulate transcription through MEF2 (Figure 5E).
To determine whether MED12 interacts with MEF2 at MEF2 consensus binding sites on calcium-han-
dling genes, we performed ChIP-reChIP experiments on nuclear fractions of  CMs isolated from CTL and 
Med12cKO ventricles. We first immunoprecipitated MED12 from sheared chromatin, as in Figure 5D, and 
subsequently immunoprecipitated the MED12-chromatin complexes with MEF2. Because MED12 pos-
itively interacts with regions of  Atp2a2 and Ryr2 at conserved MEF2 binding sites (Figure 5D and Sup-
plemental Figure 4B), we used the same sites as a readout for MED12-MEF2 ChIP-reChIP experiments. 
MED12 and MEF2 co-occupy the same conserved MEF2 consensus sites on Atp2a2 and Ryr2, but they 
do not co-occupy conserved CEBP and CREB consensus sites on Atp2a2, conserved STAT1 and STAT3 
consensus sites on Ryr2, or regions devoid of  predicted TFBS (nc) (Figure 5F). As an additional negative 
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control, NFκB did not bind to or co-occupy the conserved CEBP, MEF2, CREB, EGR1, STAT3, or STAT1 
consensus sites on Atp2a2, Gja1, Ryr2, Pln, or Cacna1d with MED12 (Supplemental Figure 4, F and G). Our 
results confirm previous ChIP-seq data in HL-1 CMs, demonstrating that ChIP peaks from exogenously 
overexpressed MEF2 are detected within Atp2a2 and Ryr2 (33). To further define MEF2 binding sites in 
CTL and Med12cKO ventricles, we performed MEF2 ChIP-seq on endogenous MEF2. We validated the 
MEF2 ChIP-seq peaks by performing de novo motif  discovery using the top 8,000 peaks identified in ven-
tricular samples (34), and the top motif  identified has been previously reported for MEF2 (Supplemental 
Figure 5A). MEF2 peaks were identified within many of  the calcium-handling genes regulated by MED12, 
including Atp2a2 (Figure 5G), Ryr2, Pln, and Cacna1d (Supplemental Figure 5). We did not observe any sig-
nificant differences in MEF2 binding in the presence or absence of  MED12. These data demonstrate that 
MED12 is not required for MEF2-DNA interaction.
Given that the Mediator kinase submodule regulates RNA Pol II recruitment and, therefore, tran-
scriptional activation, we investigated the specific role of  MED12 and its effect on Pol II–DNA binding. 
We performed RNA Pol II ChIP-seq on endogenously expressed Pol II in ventricles from CTL and Med-
12cKO mice. We did not observe significant differences in RNA Pol II binding in the presence or absence 
of  MED12. Specific results are shown for the calcium genes of  interest (Figure 5G and Supplemental 
Figure 5). These data suggest that MED12 is not required for RNA Pol II recruitment to transcription 
start sites in the heart.
MED12 directly stimulates MEF2 transcriptional activity. To investigate whether MED12 activates MEF2 
transcriptional activity, we performed luciferase reporter assays with a synthetic 3XMEF2 luciferase pro-
moter, which is activated by MEF2 (35). Interestingly, MED12 activated endogenous MEF2 transcriptional 
activity in COS-7 cells, shown by a 2-fold increase in normalized luciferase activity compared with basal 
luciferase activity (HA-VP16). Luciferase activity was increased 50-fold over basal luciferase activity in the 
presence of  active MEF2 (MEF2 HA-VP16). The addition of  MED12 increased MEF2 transcriptional 
activity by 6-fold, and MED12 and MEF2 synergistically activated luciferase activity by 340-fold over basal 
luciferase activity (Figure 5H).
Our in vivo data demonstrate that MED12 is necessary to maintain normal expression of  calcium-han-
dling genes in the heart. To determine whether MED12 is sufficient to regulate calcium-handling genes 
through MEF2, we expressed MED12 and MEF2 in HL-1 CMs. MED12 and MEF2 alone increased 
expression of  Atp2a2, Pln, and Ryr2 in CMs. Coexpression of  MED12 and MEF2 had an additive effect 
on the expression of  Atp2a2 and Pln, but not Ryr2 (Figure 5I). Collectively, our studies demonstrate that 
MED12 is required to maintain normal cardiac function by transcriptionally regulating calcium-handling 
genes through interaction with transcription factors such as MEF2.
Discussion
In this study, we investigated the function of  MED12 in the postnatal heart. We demonstrate that MED12 
is required to maintain cardiac function by regulating calcium cycling in CMs. MED12 regulates gene 
expression, in part, by coordinating transcription through multiple transcription factors known to regulate 
calcium-handling genes, including MEF2. Our results support a role for MED12 as a transcriptional regu-
lator that controls the transcriptional network of  calcium-handling genes in the heart.
Cardiac contractility is controlled at the molecular level by calcium flux. Release and reuptake of  intra-
cellular calcium drives contraction and relaxation, and this process is tightly regulated in CMs (Figure 6). 
Disruption of  calcium-handling genes results in altered cardiac contractility. For example, reduced RyR 
Figure 5. MED12 facilitates cooperative transcription of calcium-handling genes in the heart. (A) Upstream regulator analysis (URA) of differentially 
expressed genes in CTL and cKO ventricles. Bars in green are transcription factors known to regulate calcium-handling genes. (B) Circos plot demonstrating 
transcription factor binding sites (TFBS) within MED12 target genes. Genes containing TFBS for CEBP, MEF2, CREB, EGR1, STAT3, and STAT1 are categorized by 
function, and the increased width of connecting ribbons indicates more TFBS (Supplemental Table 2 contains the data used to generate the plot). (C) Chromo-
somal map of Atp2a2 with TFBS and ChIP-PCR assay primers. (D) MED12 ChIP-PCR results for select calcium-handling genes. PCR assay number corresponds 
to sequences on chromosomal maps for the indicated genes (see Supplemental Figure 4). Regions devoid of transcription factor binding sites were used as 
negative controls (nc). n = 4. (E) Coimmunoprecipitation of MED12 with MEF2 in nuclei isolated from CTL and cKO cardiomyocytes. (F) MED12-MEF2 ChIP-re-
ChIP on Atp2a2 and Ryr2 promoters, PCR assay number corresponds to sequences on chromosomal maps (see C and Supplemental Figure 4). n = 4. (G) RNA 
Polymerase II and MEF2 ChIP-seq signals at the Atp2a2 locus in CTL and cKO ventricles. MEF2 motif locations are shown in green. (H) MEF2 luciferase reporter 
assays performed in COS-7 cells. n = 3 independent experiments. Luc, luciferase. (I) Coexpression studies performed in HL-1 cardiomyocytes. n = 3 independent 
experiments. Data are average ± SEM. *P < 0.01 by 2-tailed Student’s t test (D, F, I) or one-way ANOVA with post-hoc Tukey test (H).
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protein levels in adult mouse hearts decreases heart rate and cardiac function, similar to Med12cKO mice 
(5). CMs from PLN-null (Pln-/-) mice display increased Ca2+ transient amplitude and faster Ca2+ decay 
rate, as seen in Med12cKO CMs (6). SERCA2a-null (Atp2a2-/-) mice are embryonically lethal, but hetero-
zygous mice have impaired intracellular calcium homeostasis and decreased contractile function (7). It is 
also interesting to note that Egr1, a transcription factor predicted as an upstream regulator in Med12cKO 
hearts, is the only transcription factor that is significantly downregulated in Med12cKO hearts (Figure 5A). 
Egr1-/- mice have decreased levels of  RyR, SERCA2a, and PLN, similar to Med12cKO mice (Figure 3) (36). 
Indeed, many characteristics of  Med12cKO hearts mimic those reported for calcineurin transgenic mice. 
Calcineurin transgenic mice display significant cardiac dysfunction, while isolated transgenic CMs have 
faster cytosolic calcium decay rates and duration of  calcium transients. Additionally, PLN phosphorylation 
is enhanced in transgenic mice, and CX43 is also significantly decreased (37). The phenotypic similarities 
between these mouse models and Med12cKO mice provide additional evidence that MED12 is indeed a 
regulator of  calcium-handling genes in the heart.
One way that MED12 regulates calcium-handling genes in CMs is by stimulating the transcriptional 
activity of  MEF2 (Figure 5). We demonstrated that MED12 and MEF2 co-occupy MEF2 consensus sites 
within several genes, and that MED12 and MEF2 interact in CMs. Overexpression of  MEF2 and MED12 
also increases expression of  calcium-handling genes (Figure 5). Under basal conditions, MEF2 activity 
is repressed by class II histone deacetylases (HDACs), but HDACs are posttranslationally modified by 
Ca2+-responsive kinases, consequently relieving repression of  MEF2 transcriptional activity (38, 39). MEF2 
also cooperates with other transcription factors to drive expression of  target genes (40). Our data suggest 
Figure 6. MED12 coordinates calcium cycling in cardiomyocytes. Proper Ca2+ cycling and Ca2+-dependent signaling is required to maintain normal 
cardiac contractility. Excitation-contraction (EC) coupling is initiated by an action potential which depolarizes the sarcolemma by rapid sodium influx 
through sodium channels (Scn10a). Depolarization activates voltage-gated L-type Ca2+ channels, and Ca2+ influx triggers calcium-induced calcium 
release from the SR via the ryanodine receptor (Ryr2). Rapid release of Ca2+ from the SR increases free intracellular Ca2+, enabling muscle contraction. 
Gap junctions comprised of connexin complexes (Gja1 and Gja5) connect neighboring cells and facilitate the dispersion of action potentials throughout 
the heart. Cardiomyocyte relaxation is regulated by signaling pathways that restore intracellular and SR Ca2+ to resting concentrations. Ca2+-activated 
kinases phosphorylate phospholamban (Pln), relieving its repression on SERCA2a (Atp2a2). Consequently, SERCA2a rapidly imports Ca2+ into the SR, 
decreasing the intracellular Ca2+ concentration. Na+/Ca2+ exchangers (NCX) (Slc8a2) are allosterically activated by Ca2+ and aid in restoring resting Ca2+ 
concentrations, and decreased cytosolic Ca2+ leads to relaxation of the sarcomere. Genes downregulated in Med12cKO hearts are denoted by a blue 
downward arrow and genes upregulated are denoted by a red upward arrow.
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that, in CMs, MED12 is also an important coregulator of  MEF2 transcriptional activity and may help 
recruit other transcription factors to regulate MEF2 target genes. Interestingly, MED12 and MEF2 have 
been independently shown to activate transcription of  Wnt and sonic hedgehog target genes in Drosophila 
(41–43). In the mammalian heart, however, MED12 and MEF2 seem to function as regulators of  calci-
um-handling genes. In future work, it will be important to determine the mechanism by which MED12 
regulates MEF2 transcriptional activity.
Very little is known about the specific role of  Mediator subunits in the heart (44, 45). In an effort to 
understand the physiological functions of  Mediator, mouse models of  several Mediator subunits have 
been generated. Mice with missense mutations in Med30 develop DCM after weaning. Early lethality in 
these mice was linked to a decline in mitochondrial function, likely due to decreased expression of  genes 
involved in oxidative phosphorylation in the heart (46). We recently demonstrated that cardiac MED13 
regulates metabolic gene expression in the heart. Increased expression of  Med13 enhances metabolism 
and protects mice from diet-induced obesity, and we have evidence that circulating factors in these mice 
regulate body weight (15, 16). MED1 regulates development in multiple organs, and Med1-null and hypo-
morphic mice, both of  which are embryonically lethal, have cardiac developmental defects (47, 48). It 
was recently reported by two independent groups that cardiac-specific deletion of  Med1 leads to severe 
DCM and premature death in mice. Although many calcium-handling genes were downregulated in the 
Med1-/- heart, they were measured after the onset of  DCM, which has been associated with decreased 
calcium-handling gene expression, as discussed above (49, 50).
Mutations in several Mediator subunits have been linked to congenital heart disease. Patients with 
DiGeorge syndrome have hemizygous deletions within Med15 and often present with congenital heart 
defects (51), and missense mutations in Med13l have also been linked to patients with congenital heart 
defects (52). Interestingly, some male patients diagnosed with FG/Opitz-Kaveggia syndrome have a single 
missense mutation in Med12 and suffer from congenital heart defects (53, 54). Because Med12 is on the 
X-chromosome, clinical reports of  patients with congenital Med12 mutations have been males, likely due 
to the severity of  disease symptoms in male patients. Recently, however, somatic mutations in Med12 have 
been reported in several types of  cancer in females, including uterine leiomyoma and breast fibroadenoma 
(55, 56). Additionally, our data suggest that random inactivation of  Med12 in female hearts causes cardiac 
dysfunction (αMhc-Cre+Med12fl/+, Supplemental Figure 1). These studies provide evidence that MED12 is 
also important in regulating non–X-linked diseases. Given the prominent role of  Mediator in transcrip-
tional regulation in all cell types, it is likely that these discoveries are the first of  many to identify diseases 
associated with genetic mutations in Med12. It will be interesting to investigate whether loss of  function 
mutations in Med12 might also contribute to DCM and heart failure in humans.
The Mediator kinase submodule was originally thought to act as a transcriptional repressor, but there 
is increasing evidence that kinase subunits, particularly MED12, activate transcription. In zebrafish, for 
example, mutant Med12 decreases Sox4-dependent gene expression during pancreas development, and in 
liver, mutant Med12 decreases HNF-4–dependent gene expression. Consequently, mutant Med12 prevents 
pancreatic α cell and hepatocyte differentiation, although through different mechanisms (22). Similarly, in 
another zebrafish model, mutant Med12 causes defects in craniofacial development, and MED12 is required 
for Sox9-dependent gene expression in bone and cartilage (57). In human embryonic kidney (HEK293) 
cells, MED12 interacts with β-catenin to positively regulate Wnt-mediated gene expression (58), and in 
Drosophila, MED12 is required for transcriptional activation of  Wnt target genes (41).
MED12 is ubiquitously expressed in all cell types but regulates gene expression in a cell-specific 
manner, presumably by synergizing with different transcription factors and chromatin modifiers. Indeed, 
MED12 is a corepressor of  REST, which acts to silence neuronal-specific gene expression (21), and devel-
opmental transcription factors — such as β-catenin, GLI1, and Nanog — interact with MED12 in dif-
fering cell types to help determine cell fate (42, 58, 59). Furthermore, comparison of  MED12 ChIP-seq 
peaks from mouse embryonic stem cells, mouse embryonic fibroblasts (60), and primary human or mouse 
CD34+ hematopoietic stem/progenitor cells (61) show some overlap, but MED12 localizes to specific 
chromatin regions in different cell types. There is also evidence that MED12 has opposing functions in 
different cell types. For example, as mentioned above, MED12 positively regulates Wnt target genes in 
HEK293 cells and in Drosophila (41, 58), but in Caenorhabditis elegans (C. elegans), MED12 seems to be 
an inhibitor of  Wnt/β-catenin–mediated gene expression (62, 63). We previously reported opposing met-
abolic functions of  MED13 in cardiac and skeletal muscle, yet another example of  cell-specific functions 
1 2insight.jci.org   https://doi.org/10.1172/jci.insight.91920
R E S E A R C H  A R T I C L E
of  Mediator subunits (64). Additionally, loss of  Med23 facilitates smooth muscle cell differentiation but 
represses adipocyte differentiation by regulating different sets of  genes in a cell-dependent manner (65).
Here, we focused on determining a role for MED12 in the heart. We found that MED12 is a transcrip-
tional regulator of  calcium-handling genes in CMs. Whether MED12 regulates calcium-handling genes in 
other tissues, such as skeletal muscle, is currently under investigation. Future work will investigate the roles 
of  other transcription factors that interact with MED12 in the heart. These studies will reveal additional 
transcriptional networks regulated by MED12 that are important to maintain cardiac function.
Methods
Animals. Animals were housed in a pathogen-free barrier facility with a 12-hour light/dark cycle and main-
tained on standard chow (2916 Teklad Global). The generation of  Med12fl/fl mice is published (24). Med-
12cKO were generated by crossing female Med12fl/fl mice to male mice expressing the αMhc-Cre transgene 
(26). Med12 is located on the X chromosome, and all αMhc-Cre+ male mice with a single-floxed Med12 allele 
(αMhc-Cre+Med12fl/y) are abbreviated as Med12cKO.
Histology. Hearts were isolated and fixed in 4% (vol/vol) paraformaldehyde in PBS for 48 hours at 4°C with 
gentle shaking. Hearts were dehydrated, embedded in paraffin, and sectioned. Heart sections were stained with 
H&E, Masson’s trichrome, TUNEL, propidium iodide, and Ki-67 using standard procedures. Heart sections 
were costained with cardiac Troponin T (MA5-12960, Thermo Fisher Scientific) to identify CMs.
Transmission electron microscopy. Hearts were fixed by perfusion with 4% paraformaldehyde and 1% glu-
taraldehyde in 0.1 M sodium cacodylate buffer (pH 7.4). Samples were processed by the University of  Tex-
as Southwestern Medical Center Electron Microscopy Core facility. Briefly, fixed tissues were post-fixed, 
stained, dehydrated, and embedded in EMbed-812 resin (Thermo Fisher Scientific). Tissue sections were 
cut and post-stained, and images were acquired on a FEI Tecnai G2 Spirit TEM.
Transthoracic echocardiography. Cardiac function and heart dimensions were determined by 2-dimen-
sional echocardiography using a Visual Sonics Vevo 2100 Ultrasound (Visual Sonics) on nonanesthetized 
mice. M-mode tracings were used to measure anterior and posterior wall thicknesses at end diastole and 
end systole. LVID was measured as the largest anteroposterior diameter in either diastole (LVIDD) or 
systole (LVIDS). A single observer blinded to mouse genotypes performed echocardiography and data 
analysis. Fractional shortening (FS) was calculated according to the following formula: FS(%) = ([LVIDd 
− LVIDs]/LVIDd) × 100. Ejection fraction (EF%) was calculated by: EF(%) = (EDV – ESV)/EDV, where 
ESV represents end systolic volume and EDV represents end diastolic volume.
Electrocardiography. ECG was performed on sedated adult male mice (6 weeks of  age) using Accutac 
Diaphoretic ECG Electrodes (ConMed Corp.). Electrodes were attached to all 4 limbs, and leads I, II, III, 
aVR, aVL, and aVF were recorded using PageWriter XLs (Hewlett Packard). Traces were recorded using 
identical settings for CTL and Med12cKO mice (50 mm/s; 20 mm/mV).
RNA extraction and quantitative PCR analysis. Total RNA was isolated from both ventricles of  CTL and 
Med12cKO mice using TRIzol according to the manufacturer’s instructions (Thermo Fisher Scientific). 
cDNA was synthesized using iScript Reverse Transcription Supermix with random primers (Bio-Rad). 
Gene expression was analyzed by quantitative PCR (qPCR) using KAPA SYBR FAST (Kapa Biosystems) 
on a 7900HT Fast Real-Time PCR machine (Applied Biosystems). Expression amount was normalized to 
18S mRNA and was represented as fold change.
RNA deep sequencing analysis. Total RNA was isolated from both ventricles of  male P1 CTL and 
Med12cKO mice using TRIzol according to the manufacturer’s instructions. Illumina RNA-Seq was per-
formed by the University of  Texas Southwestern Microarray Core Facility. Quality assessment of  the 
RNA-Seq data was performed using NGS-QC-Toolkit (v 2.3.3) with default settings (66). Quality filtered 
reads were aligned to the mouse reference genome GRCm38 (mm10) using the Tophat2 (v 2.0.0) aligner 
with default settings (67). The R package DESeq2 (v 1.6.3) was used for differential gene expression anal-
ysis (68). Read counts obtained from featureCounts were normalized by taking the median of  each gene 
count across samples and dividing each sample gene count by the relative ratio of  library sizes between 
the calculated median and sample size (69). The average normalized expression values of  the samples 
were used to calculate fold change and P values. Cutoff  values of  fold change greater than 1.5 and P < 
0.05 were then used to select for differentially expressed genes between sample group comparisons.
Significant pathway enrichment analysis was performed using Ingenuity Pathways Analysis (Ingenu-
ity Systems). Fisher’s exact test was used to calculate the p-value and determine the probability that each 
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biological function was enriched in the dataset due to chance alone. Statistically significant biological path-
ways were then identified by selection for pathways with P < 0.05.
The DAVID gene functional annotation and classification tool was used to annotate the list of  differen-
tially expressed genes with respective GO terms and GO enrichment analysis for molecular and biological 
functional categories was performed. Functional GO groups were selected for significance by using a P 
value cutoff  of  1% (70). For both IPA and GO enrichment analysis, nonredundant pathways and functions 
are reported.
To identify upstream transcriptional regulators of  gene expression in the analyzed dataset, IPA URA 
was performed, and activation z-scores were computed.
In silico analysis. The SynoR tool was used to predict genes that are cooperatively regulated by multi-
ple transcription factors (32). Multiple groups of  transcription factors, predicted by IPA to regulate gene 
expression in Med12cKO hearts, were analyzed to identify the genes they synonymously regulate. Regula-
tion of  these genes was then biochemically tested using ChIP analysis.
Adult mouse CM isolation. Adult mouse hearts were rapidly excised, and the aorta was cannulated on a 
constant-flow Langendorff  perfusion apparatus. Hearts were digested with perfused Tyrode’s solution (10 
mM glucose, 5 mM HEPES, 5.4 mM KCl, 1.2 mM MgCl2, 150 mM NaCl, 2 mM sodium pyruvate, pH 7.4) 
(Sigma-Aldrich) containing Liberase (0.25 mg/ml) (Roche Diagnostics), and the ventricles were minced, 
filtered, and equilibrated with Tyrode’s solution containing 1 mM CaCl2 (Sigma-Aldrich) and BSA (Gem-
ini) at room temperature (15).
Neonatal mouse CM isolation. Neonatal mouse hearts were extracted, and neonatal mouse CMs were iso-
lated from both ventricles using the Isolation System for Neonatal Rat/Mouse CMs (Cellutron) according 
to the manufacturer’s instructions.
CM intracellular calcium and contractility measurements. Adult and neonatal CMs were loaded with 0.5 
μM Fura-2-AM (Molecular Probes) and placed in a heated chamber (37°C) on the stage of  an inverted 
microscope. The chamber was perfused with Tyrode’s solution containing CaCl2 (1.8 mM), glucose (10 
mM), HEPES (5 mM), KCl (5.4 mM), MgCl2 (1.2 mM), NaCl (150 mM), and sodium pyruvate (2 mM) 
(pH 7.4) (Sigma-Aldrich). An IonOptix Myocyte Calcium and Contractility System was used to pace 
CMs at 0.5 Hz with a MyoPacer field stimulator (IonOptics), and changes in intracellular Ca2+ levels 
were monitored using Fura-2 dual-excitation (340/380 nm) (Molecular Probes), single emission (510 
nm) ratiometric imaging. For SR load measurements, field stimulation was stopped and 10 mM caffeine 
(Sigma-Aldrich) was rapidly applied to the cells. Peak Ca2+ transient amplitude, τ, and the duration of  
the Ca2+ transient were determined using IonWizard 6.0 analysis software (IonOptix) (71). Adult CM 
contractility measurements were made using sarcomere length (SarcLen) parameters and processed with 
IonWizard 6.0 software.
Nuclear fractionation and immunoprecipitation. Nuclear extracts were isolated from CMs using the 
NE-PER Nuclear and Cytoplasmic Extraction Kit (Pierce) according to manufacturer’s instructions. 
Nuclear extracts were incubated with a MED12 antibody (A300-774A, Bethyl Laboratories) overnight 
and immunoprecipitated the following day using Dynabeads (Thermo Fisher Scientific) according the 
manufacturer’s protocol. After excessive washing, the bound protein was boiled off  the Dynabeads and 
resolved on a 4%–20% precast polyacrylamide gel.
ChIP and ChIP-reChIP. Nuclear extracts isolated from adult CMs were used to perform ChIP and 
ChIP-reChIP. Nuclei were crosslinked, with formaldehyde (final concentration of  2%) for 60 minutes at 
room temperature with gentle shaking (72). The cross-linking reaction was terminated by adding glycine 
for 10 minutes, and crosslinking was reversed by overnight incubation at 65°C. Sheared chromatin was 
immunoprecipitated with an antibody against MED12 (A300-774A, Bethyl Laboratories) or NFκB p50 
(sc-1190 X, Santa Cruz Biotechnology Inc.) (73), and DNA was isolated and analyzed by PCR with 
primers flanking binding sites for the indicated TFBS. For ChIP-reChIP, sheared chromatin was immu-
noprecipitated with an antibody against MED12 (A300-774A, Bethyl Laboratories), followed by immu-
noprecipitation with an antibody against MEF2 (sc313 X, Santa Cruz Biotechnology Inc.) or NFκB p50 
(sc-1190 X, Santa Cruz Biotechnology Inc.), and DNA was isolated and analyzed by PCR with primers 
flanking binding sites for the indicated TFBS or regions devoid of  TFBS as nc. Results are normalized to 
input and reported as percent input.
ChIP-seq. ChIP was performed as described above, and ChIP-seq libraries were constructed using the 
Kapa Hyper Prep Kit (KK8500, Roche) according to the manufacturer’s instruction. Raw reads were 
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mapped using Bowtie2 to obtain about 50 million uniquely mapped single end reads per library (74). Peak 
calling was performed by MACS/MACS2 (75). The resulting output files included the peak list in BED for-
mat, ChIP signal in bedgraph format, and mapped reads in BAM format. All files were subjected to integra-
tive in-depth analysis with published data and data generated by the Encode project using the Bioconductor 
software project site (76). De novo motif  discovery in MEF2 ChIP-seq peak regions were identified using 
Regulatory Sequence Analysis Tools (RSAT) (34). ChIP-seq data tracks for MEF2 and RNA Poll II were 
visualized using Integrative Genomics Viewer available online from the Broad Institute, and figures were 
generated using this software (77).
Immunoblotting. Protein was isolated from homogenized ventricles in modified RIPA buffer. Protein 
(10 μg) was loaded per sample, and proteins were detected using the following antibodies: MED12 (A300-
774A, Bethyl Laboratories), RyR (C3-33, Pierce), SERCA2a (2A7-A1, Pierce), total PLN (2D12, Pierce), 
pSer16 PLN (A010-12, Badrilla), pThr17 PLN (A010-13, Badrilla), Connexin 43 (ab11370, Abcam), 
MEF2 (sc-313, Santa Cruz Biotechnology Inc.), and GAPDH (MAB374, Millipore).
Cell culture, transfection, and luciferase reporter assays. For luciferase reporter assays, COS-7 cells 
(CRL-1651; ATCC) were grown in DMEM containing 10% FBS. Transfections were performed with 
FuGENE 6 Transfection Reagent (Promega) according to the manufacturer’s instructions. Cells were 
plated in 6-well dishes, and after 12 hours of  incubation, transfections were performed. Plasmid DNA 
(100 ng of  total) was used for all conditions. All luciferase plasmids have been previously described (35, 
78). Med12 was cloned into p3XFLAG-CMV-10 vector, and a CMV promoter–driven LacZ expression 
plasmid was included for all transfections as an internal control. Cells were lysed 48 hours after trans-
fection, and luciferase activity (Promega) and β-galactosidase activity (Invitrogen) were determined 
according to the manufacturer’s instructions.
HL-1 cells, a CM-derived cell line (79), were a gift from the WC Claycomb laboratory. HL-1 CMs 
were cultured according to the protocol and plated in 6-well dishes, and after 12 hours of  incubation, 
transfections were performed with FuGENE 6 Transfection Reagent (Promega) according to the man-
ufacturer’s instructions. Mef2C was cloned into a pcDNA vector containing a CMV promoter, the 
same Med12 plasmid was used as described for the luciferase assays, and a GFP plasmid was used as 
a control. GFP fluorescence was detected in HL-1 CMs 12 hours after transfection. Cells were lysed 
24 hours after transfection, total RNA was isolated, gene expression was analyzed by qPCR, and 
expression was normalized to 18S mRNA. Data is represented as fold change compared with GFP 
transfected cells.
Statistics. All data are expressed as mean ± SEM. Two-tailed Student’s t test or one-way ANOVA with 
post hoc Tukey’s test was performed to determine statistical significance, and the analysis is specified in the 
figure legends. A P < 0.05 was considered statistically significant.
Study approval. All animal procedures were approved by the IACUC at University of  Texas Southwestern 
Medical Center.
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